Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction

被引：22

作者：

Sui, ZH ^{[1
]}

Guan, JH ^{[1
]}

Macielag, MJ ^{[1
]}

Jiang, WQ ^{[1
]}

Zhang, SY ^{[1
]}

Qiu, YH ^{[1
]}

Kraft, P ^{[1
]}

Bhattacharjee, S ^{[1
]}

John, TM ^{[1
]}

Haynes-Johnson, D ^{[1
]}

Clancy, J ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Raritan, NJ 08869 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2002年 / 45卷 / 19期

关键词：

D O I：

10.1021/jm025545d

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of N-pyrimidinylpyrroloquinolones were discovered as extremely potent and selective PDE5 inhibitors. Representative compounds demonstrated in vivo efficacy in dog erectile dysfunction models and are orally bioavailable.

引用

页码：4094 / 4096

页数：3

共 50 条

[21] The discovery of novel, potent and selective PDE5 inhibitors
Bi, YZ
Stoy, P
Adam, L
He, B
Krupinski, J
Normandin, D
Pongrac, R
Seliger, L
Watson, A
Macor, JE
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2461 - 2464
[22] Psychological Predictors of PDE5 Inhibitors in Vasculogenic Erectile Dysfunction
Palmas, Artur
Pascoal, Patricia
Nobre, Pedro
[J]. INTERNATIONAL JOURNAL OF SEXUAL HEALTH, 2019, 31 : A568 - A568
[23] PDE5 inhibitors: Is there more to come besides erectile dysfunction?
Stief, Christian
[J]. EUROPEAN UROLOGY, 2007, 52 (04) : 943 - 944
[24] PDE5 INHIBITORS FAILURES IN ERECTILE DYSFUNCTION - WHAT ARE THE CAUSES?
Fedorova, Anna
Vykhodtcev, Sergei
Lukyanov, Andrey
[J]. JOURNAL OF SEXUAL MEDICINE, 2017, 14 (05): : E306 - E306
[25] Selective N-pyrimidinyl pyrroloquinolone PDE5 inhibitors as agents for treatment of male erectile dysfunction.
Jiang, WQ
Sui, ZH
Guan, JH
Macielag, MJ
Zhang, SY
Qiu, YH
Kraft, P
Bhattacharjee, S
Lombardi, E
Haynes-Johnson, D
John, TM
Clancy, J
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U56 - U56
[26] Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction (vol 89, 103022, 2019)
Reddy, G. Lakshma
Dar, Mohd. Ishaq
Hudwekar, Abhinandan D.
Mahajan, Priya
Nargotra, Amit
Baba, Adil Manzoor
Nandi, Utpal
Wazir, Priya
Singh, Gurdarshan
Bharate, Sonali S.
Vishwakarma, Ram A.
Syed, Sajad Hussain
Sawant, Sanghapal D.
[J]. BIOORGANIC CHEMISTRY, 2019, 92
[27] Highly selective chiral PDE5 inhibitors for treatment of MED.
Bunnage, ME
Mathias, JP
Street, SDA
Wood, A
Ballard, SA
Beaumont, KC
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U72 - U72
[28] Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer's rule
Bunnage, Mark E.
Mathias, John P.
Wood, Anthony
Miller, Duncan
Street, Stephen D. A.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (23) : 6033 - 6036
[29] Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED
Boyle, CD
Xu, R
Asberom, T
Chackalamannil, S
Clader, JW
Greenlee, WJ
Guzik, H
Hu, YQ
Hu, ZY
Lankin, CM
Pissarnitski, DA
Stamford, AW
Wang, YG
Skell, J
Kurowski, S
Vemulapalli, S
Palamanda, J
Chintala, M
Wu, P
Myers, J
Wang, P
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2365 - 2369
[30] Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities
Maria Puigvert, Ana
Prieto, Rafael
Garcia, Ferran
[J]. REVISTA INTERNACIONAL DE ANDROLOGIA, 2018, 16 (01): : 28 - 33

← 1 2 3 4 5 →